Oral infection and rheumatic diseases

Česká verzia

Authors: Leona Procházková; Miroslav Souček
Authors place of work: Revmatologická ambulance II. interní kliniky LF MU a FN u sv. Anny, Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2014; 60(2): 128-133
Category: Review

Summary

Periodontitis (PD) is one of the most common infectious diseases of dental attachment. From epidemiological studies there is known association of periodontitis with chronic diseases as for example diabetes mellitus, cardiovacular diseases, atherosclerosis or Crohn disease. In last decade there is an increasing evidence for association of rheumatoid arthritis (RA) and periodontitis also. RA and PD have some common genetic, environmental and immunopathological characters. Important aspect of reciprocal relationship is also ability to citrullination, which is innate to one of most important oral patogen – Porphyromonas gingivalis. Citrullination and production of autoantibodies against this modified proteins is one the important pathophysiological actions in course of RA. Recently, there has been published papers drawing attention to potential influence of periodontitis therapy to course and activity of RA. Furthermore there appear some information pointing to possible association between PD and other rheumatic diseases as for example spondyloarthritis. Interrelationship between PD and rheumatic diseases thus stay important and still open question in research of pathophysiology, course and therapeutic possibilities of rheumatic diseases.

Key words:
citrullination – periodontitis – Porphyromonas gingivalis – rheumatoid arthritis

Zdroje

1. Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012; 8(10): 573–586.

2. Lundstrom E, Kallberg H, AlfredsssonL et al. Gene-enviroment interactions between the DRB1 shared epitope and smoking in the risk of anti citrullinated protein antibody-positive rheumatoid arthritis: al alleles important. Arthritis Rheum 2009; 60(6): 1597–1603.

3. Forner L, Nielsen CH, Bendtzen K et al. Increased plasma levels of IL-6 in bacteremic periodontis patients after scaling. J Clin Periodontol 2006; 33(10): 724–729.

4. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000. 2002; 28: 12–55.

5. Tobón GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease. Rheumatoid arthritis. J Autoimmun 2010; 35(1): 10–14.

6. Walter C, Zahlten J, Schmeck B et al. Porphyromonas gingivalis straindependent activation of human endothelial cells. Infect Immun 2004; 72(10): 5910–5918.

7. Page RC, Eke PI. Case definitions for use in population-based surveillance of periodontitis. J Periodontol 2007; 78(7 Suppl): 1387–1399.

8. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000. 2002; 28: 12–55.

9. Müller HP. Parodontologie. Thieme Georg Verlag: Stuttgart, New York 2001. ISBN 313126361X, 9783131263612.

10. de Heens GL, Kikkert R, Aarden LA et al. Effects of smoking on the ex vivo cytokine production in periodontitis. J Periodontal Res 2009; 44(1): 28–34.

11. Zhang W, Song F, Windsor LJ. Cigarette smoke condensate affects the collagen-degrading ability of human gingival fibroblasts. J Periodontal Res 2009; 44(6): 704–713.

12. Rutger PG. Rheumatoid arthritis and periodontitis – inflammatory and infectious connections. Review of the literature. J Oral Microbiol 2012; 4. Dostupné z DOI: <http://doi: 10.3402/jom.v4i0.11829>.

13. Chun YH, Chun KR, Olguin D et al. Biological foundation for periodontitis as a potentional risk factor for atherosclerosis. J Clin Periodontal Res 2005; 40(1): 87–95.

14. Routsias JG, Goules JD, Goules A et al. Autopathogenic correlation of periodontitis and rheumatoid arthritis. Rheumatology (Oxford) 2011; 50(7): 1189–1193.

15. Rosenstein E, Greenwald RA, Kushner LJ et al. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004; 28(6): 311–318.

16. Schellekens GA, de Jong BA, van den Hoogen FH et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101(1): 273–281.

17. Schellekens GA, Visser H, de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing acyclic citrullinated peptide. Arthritis Rheum 2000; 43(1): 155–163.

18. Wegner N, Wait R, Sroka A et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010; 62(9): 2662–2672.

19. Janssen H, Koen MJ et al. Lessons to be learned from periodontitis. Curr Opin Rheumatol 2013; 25(2):241–247.

20. Berthelot JM, Le Goff B. Rheumatoid arthritis and periodontal disease. Joint Bone Spine 2010; 77(6): 537–541.

21. Chang X, Han J. Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 2006; 45(3): 183–196.

22. Foulquier C, Sebbag M, Clavel C et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1. PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007; 56(11): 3541–4353.

23. Costenbader KH, Chang SC, De Vivo I et al. Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohortstudies: evidence of gene-environment interactions with heavy cigarette smoking. Arthritis Res Ther 2008; 10(3): R52 Dostupné z DOI: <http:// doi: 10.1186/ar2421>.

24. Astry B, Harberts E, Moudgil KD. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res 2011; 31(12): 927–940.

25. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002; 30(2): 340–346.

26. Hernández M, Dutzan N, García-Sesnich J et al. Host-pathogen interactions in progressive chronic periodontitis. J Dent Res 2011; 90(10): 1164–1170.

27. Fagundes JA, Monoo LD, Euzébio Alves VT et al. Porphyromonas gingivalis is associated with protease-activated receptor-2 upregulation in chronic periodontitis. J Periodontol 2011; 82(11): 1596–1601.

28. Al-Katma MK, Bissada NF, Bordeaux JM et al. Control of periodontal infection reduces the severity of active rheumatoid arthritis. J Clin Rheumatol 2007; 13(3): 134–137.

29. Ribeiro J, Leão A, Novaes AB. Periodontal infection as a possible severity factor for rheumatoid arthritis. J Clin Periodontol 2005; 32(4): 412–416.

30. Ortiz P, Bissada NF, Palomo L et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol 2009; 80(4): 535–540.

31. Kallberg H, Padyukov L, Plenge RM et al. Gene-gene and gene-environment interactions involving HLADRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80(5): 867–875.

32. Feitsma AL, van der Voort EI, Franken KL et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010; 62(1): 117–125.

33. Dierickx K, Pauwels M, Laine ML et al. Adhesion of Porphyromonas gingivalis. Serotypes to Pocket Epithelium. J Periodontol 2003; 74(6): 844–848.

34. Wegner N, Wait R, Sroka A et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010; 62(9): 2662–2672.

35. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369 369(9570):1379–1390.

36. Pischon N, Pischon T, Gülmez E et al. Periodontal disease in patients with ankylosing spondylitis. Ann Rheum Dis 2010; 69(1): 34–38.

37. Keller JJ, Kang JH, Lin HC. Association between ankylosing spondylitis and chronic periodontitis: a population-based study. Arthritis Rheum 2013; 65(1): 167–173.

38. Wendling D, Prati C. Spondyloarthritis and smoking: towards a new insight into the disease. Expert Rev Clin Immunol 2013; 9(6): 511–516.

39. Schenkein HA et al. IL-17 in Sera from Patients with Aggressive Periodontitis. J Dent Res 2010; 89(9): 943–947.

40. Soto-Rojas AE, Kraus A. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. Arch Med Res 2002; 33(2): 95–106.

41. Kuru B, McCullough MJ, Yilmaz S et al. Clinical and microbiological studies of periodontal disease in Sjögren syndrome patients. J Clin Periodontol 2002; 29(2): 92–102.

42. Ozcelik O, Haytac MC, Ergin M et al. The immunohistochemical analysis of vascular endothelial growth factors A and C and microvessel density in gingival tissues of systemic sclerosis patients: their possible effects on gingival inflammation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105(4): 481–485.

43. Kobayashi T, Ito S, Yamamoto K et al. Risk of periodontitis in systemic lupus erythematosus is associated with Fcgamma receptor polymorphisms. J Periodontol 2003; 74(3): 378–384.

44. Sales LAR, Vassalo S, Chaves MGAM et al. Periodontal disease and systemic lupus erythematosus activity. Revista Interdisciplinar de Estudos Experimentais 2009; 1(1): 14–20.

45. Bodnár N, Szekanecz Z, Prohászka Z et al. Anti-mutated citrullinated vimentin (anti-MCV) and anti-65 kDa heat shock protein (anti-hsp65): New biomarkers in ankylosing spondylitis. Joint Bone Spine 2012; 79(1): 63–66.

46. Hitchon CA, Chandad F et al. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol 2010; 37(6): 1105–1112.

47. Moen K, Brun JG, Valen M et al. Synovial inflammation in rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol 2006; 24(6): 656–663.